DOCSLIB.ORG

Please Withhold My Identity and Any Identifying Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Please Withhold My Identity and Any Identifying Information 1 PLEASE WITHHOLD MY IDENTITY AND ANY IDENTIFYING INFORMATION My Story • Name: • Age: • My address is: • My postal address is: [same as above] • You can contact me on: • I want my story to be public 2 3 April 2016 Committee Secretary Senate Standing Committees on Community Affairs PO Box 6100 Parliament House Canberra ACT 2600 I am writing this submission as I have one of the co-infections that is tested for and treated by members of the Australian Chronic Infectious Diseases Society (ACIDS) in their investigations into chronic infections among their patients. I have seen Australians with Lyme-like illness suffer the devastating effects of their infections. I have observed the lack of support given to them in their efforts to obtain appropriate diagnosis and treatment. Like them, I have been dismissed, disregarded, given inappropriate treatment and repeatedly failed by the general medical profession over a long period of time. I wish to tell my story to highlight the fact that important consideration needs to be given to the co-infection Chlamydia pneumoniae, also known as Chlamydophila. This is covered by section g (any other related matters) in the enquiry’s terms of reference. My Journey I have been sick for 16 years. Prior to falling ill, my life was good. I was happily married with two young children. I had never been affected by serious illness. Importantly, I had a normal physiological response to stress and did not suffer from depression or anxiety. I began to experience unusual pain symptoms in 2000. My condition steadily deteriorated until by 2005 my life had become virtually unlivable. Relief did not come until 2010. I have positive blood tests from (USA) confirming a chronic active Chlamydia pneumoniae infection. My journey has involved 31 doctors and medical practitioners. I have received a diagnosis of ‘fibromyalgia’ and chronic myofascial pain. Consideration of Co-Infection Chlamydia pneumoniae Finding an overseas practitioner (USA) who had expertise in treating my debilitating symptoms was the turning point in my illness. This medical practitioner listened to me sympathetically and suspected that I had a chronic infection based on the symptomology that I described. Accordingly, he tested me for the co-infection Chlamydia pneumoniae. Blood tests conducted at (USA) in 2009 confirmed a chronic active infection. Chlamydia pneumoniae was acknowledged to be a new chlamydial species in 1989 (Grayston et al, 1989) and is recognised by the CDC (Centers for Disease Control and Protection) as carrying a ‘spectrum of illness [which] can range from asymptomatic infection to severe disease’1. Scientific understanding of the microorganism is incomplete. 1 CDC information on Chlamydia pneumoniae (2014) taken from National Center for Immunization and Respiratory Diseases. http://www.cdc.gov/pneumonia/atypical/chlamydophila.html 3 Its existence in Australia is not in dispute. It is described in the academic literature as an obligate intracellular parasite and is acquired through inhalation of airborne droplets expelled by an infected person. ACIDS has included it as a non tick-borne co-infection in its Borrelia and Coinfection Disease Guidelines 2014 Ver 1.51. It is recognized and treated by the International Lyme and Associated Diseases Society (ILADS). Its capacity to cause serious chronic symptoms in a subset of vulnerable individuals – irrespective of whether they have Borrelia – is not adequately understood by the general medical profession. My Symptomology Persistent pain is part of the symptomology of many Australians with Lyme-like illness and was my most prevalent symptom. On first presenting to my Australian GP in 2001 I provided a detailed, three page description of my symptoms, stating that they were so bad that I was terrified about how I would cope if they got any worse. These are summarised below: • Severe muscle stiffness on awakening • ‘Screwdriver embedded in spine, deep in chest’ on awakening • Sensation of vertebrae being fused together • Pain in the cervical vertebrae and at the base of the skull • ‘Steel vice clamping the back of my skull’ • ‘Heavy helmet screwed into my skull all the way round’ • ‘Feeling that skull is about to burst’ • ‘Living in a nightmare’ • Excessive muscle tension • Headaches • Memory loss • Confusion • Inability to multi-task • Red, itchy skin rashes By 2005, despite repeated visits to doctors and specialists, my symptoms had worsened: • Constant pain • Cognitive impairment – slow thinking and slow speech • Widespread myofascial trigger points • Disruption of skeletal muscle physiology • Muscles stuck in shortened position • Strange buzzing sensations in muscles • Electrical-type pain; the feeling that I had negative electricity flowing through me • ‘Living rigor mortis’ • Loss of weight • Loss of appetite • Anxiety • Depression • Dizziness 4 • Insomnia • Fatigue • Panic attacks • Exaggerated startle response • Hypersensitivity to noise • Respiratory difficulties when stressed • Enlarged lymph nodes • Loss of sense of well-being The pain and symptoms were so excoriating to my sense of well being that I kept pain diaries. I could not believe that the experience I was enduring was being treated with such apparent complacency by the medical profession. Some extracts from my diary may help the committee understand the nature of the pain: 31.01.01 Woke up with terrible stiffness in chest and neck. It feels as though the spinal column has seized up. Went to see my doctor. I’m frightened in case nothing can be done. I don’t trust myself to talk so I have written it all down for her. I’ve got to come out of there with something more than a recommendation to do Feldenkrais!! I cried on the way there. Sitting in her waiting room I felt a terrible pain and I cried again. Cried when I talked to her – just as well I had written it all down. 11.02.01 Today was hell... my back gradually drove me to screaming point. In the end I lay on the carpet and cried. I tried to do all the back exercises I could think of but nothing really helped. I cried and cried. I went and fetched [my husband] and said, “How much pain must a person endure before they go insane? I have reached breaking point. I feel I have suffered hours of torture every day for the last few months.” “Enough is enough,” I want to yell. “I will tell you everything I know.” 22.12.04 One of the worst days of my life. Dreadful, dreadful pain in my neck and head... As we made our way to the back of the bus I was crying with pain and a man said to me ‘I can tell that you are in a very bad way. Do you have medication and have you taken it?’... 23.12.04 I am in a living hell. I told [my husband] last night that he would have to help me. I explained that all the blood vessels in my neck are constricted and that the blood is not getting through to my brain and therefore I cannot think very clearly. I think this is what is happening. 20.03.05 I wake up in pain. Wire wrapped around my chest, my ankles. Pain behind my knees, my thighs. Deep aching pain in my hip, especially my right hip. Pain across the back of my head, neck, upper back. It feels as though I have been walloped on the back of my head by a baseball bat. My life is not right. 5 30.01.06 Mid-morning, pain crept up again. Tightness and pain at back of head, top of head, in cheeks. Pain in balls of feet, in toes. I had a lot to do before leaving the house and the pressure built up, along with the confusion and slow brain, and of course the pain. I had a bad pain at the base of my spine and could hardly sit down. I feel like a geriatric. In the car I got relief from massaging skull, feet, neck, ears and base of spine. It feels as though this thing is creeping ever further throughout my body. 19.08.07 Half of my body is wracked and twisted and the other half feels normal. My left leg and foot feel cold. There is a hard cold pain on the left side of my skull above the ear. I can’t concentrate on anything. All I can do is sit it out. Every few minutes I twist and tug at the muscles to pull out the pain. It keeps coming back, so I have to keep twisting and pulling repeatedly, all day. There is pain in my head, neck, shoulder and hips... There is a burning, stinging feeling all over my body. 16.07.08 In this hideous, weird world of central nervous system dysfunction: the horror of trigger point injections. Lying on that table. Enduring the mind-blowing pain of muscles being probed over and over again with a fat needle. The involuntary jerking of the neck. The electrical current in the surrounding muscles. The crunch of needle against bone. 31.07.08 Dreadful day. I got a day filled with pain. Feel as bad as I ever was. Pain in multiple places all down left side of body. Very bad in ribcage, throat, back of head and neck. Also brain fog. Loss of train of thought. I start something, forget what I’m doing, then start doing something else – but anything, not necessarily something connected to the first thing. I feel I will never achieve anything again. My life is virtually over. I feel very, very ill. Not right in head, not right in body. Living in a nightmare. Why, why, why? Malaise. I would rather be dead. My head has been unscrewed and screwed back on again all wrong.
Load more

Recommended publications
  • Compendium of Measures to Control Chlamydia Psittaci Infection Among
    Compendium of Measures to Control Chlamydia psittaci Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2017 Author(s): Gary Balsamo, DVM, MPH&TMCo-chair Angela M. Maxted, DVM, MS, PhD, Dipl ACVPM Joanne W. Midla, VMD, MPH, Dipl ACVPM Julia M. Murphy, DVM, MS, Dipl ACVPMCo-chair Ron Wohrle, DVM Thomas M. Edling, DVM, MSpVM, MPH (Pet Industry Joint Advisory Council) Pilar H. Fish, DVM (American Association of Zoo Veterinarians) Keven Flammer, DVM, Dipl ABVP (Avian) (Association of Avian Veterinarians) Denise Hyde, PharmD, RP Preeta K. Kutty, MD, MPH Miwako Kobayashi, MD, MPH Bettina Helm, DVM, MPH Brit Oiulfstad, DVM, MPH (Council of State and Territorial Epidemiologists) Branson W. Ritchie, DVM, MS, PhD, Dipl ABVP, Dipl ECZM (Avian) Mary Grace Stobierski, DVM, MPH, Dipl ACVPM (American Veterinary Medical Association Council on Public Health and Regulatory Veterinary Medicine) Karen Ehnert, and DVM, MPVM, Dipl ACVPM (American Veterinary Medical Association Council on Public Health and Regulatory Veterinary Medicine) Thomas N. Tully JrDVM, MS, Dipl ABVP (Avian), Dipl ECZM (Avian) (Association of Avian Veterinarians) Source: Journal of Avian Medicine and Surgery, 31(3):262-282. Published By: Association of Avian Veterinarians https://doi.org/10.1647/217-265 URL: http://www.bioone.org/doi/full/10.1647/217-265 BioOne (www.bioone.org) is a nonprofit, online aggregation of core research in the biological, ecological, and environmental sciences. BioOne provides a sustainable online platform for over 170 journals and books published by nonprofit societies, associations, museums, institutions, and presses. Your use of this PDF, the BioOne Web site, and all posted and associated content indicates your acceptance of BioOne’s Terms of Use, available at www.bioone.org/page/terms_of_use.
    [Show full text]
  • Pdf/Bookshelf NBK368467.Pdf
    BMJ 2019;365:l4159 doi: 10.1136/bmj.l4159 (Published 28 June 2019) Page 1 of 11 Practice BMJ: first published as 10.1136/bmj.l4159 on 28 June 2019. Downloaded from PRACTICE CLINICAL UPDATES Syphilis OPEN ACCESS Patrick O'Byrne associate professor, nurse practitioner 1 2, Paul MacPherson infectious disease specialist 3 1School of Nursing, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada; 2Sexual Health Clinic, Ottawa Public Health, Ottawa, Ontario K1N 5P9; 3Division of Infectious Diseases, Ottawa Hospital General Campus, Ottawa, Ontario What you need to know Box 1: Symptoms of syphilis by stage of infection (see fig 1) • Incidence rates of syphilis have increased substantially around the Primary world, mostly affecting men who have sex with men and people infected • Symptoms appear 10-90 days (mean 21 days) after exposure with HIV http://www.bmj.com/ • Main symptom is a <2 cm chancre: • Have a high index of suspicion for syphilis in any sexually active patient – Progresses from a macule to papule to ulcer over 7 days with genital lesions or rashes – Painless, solitary, indurated, clean base (98% specific, 31% sensitive) • Primary syphilis classically presents as a single, painless, indurated genital ulcer (chancre), but this presentation is only 31% sensitive; – On glans, corona, labia, fourchette, or perineum lesions can be painful, multiple, and extra-genital – A third are extragenital in men who have sex with men and in women • Diagnosis is usually based on serology, using a combination of treponemal and non-treponemal tests. Syphilis remains sensitive to • Localised painless adenopathy benzathine penicillin G Secondary on 24 September 2021 by guest.
    [Show full text]
  • 2020 European Guideline on the Management of Syphilis
    DOI: 10.1111/jdv.16946 JEADV GUIDELINES 2020 European guideline on the management of syphilis M. Janier,1,* M. Unemo,2 N. Dupin,3 G.S. Tiplica,4 M. Potocnik, 5 R. Patel6 1STD Clinic, Hopital^ Saint-Louis AP-HP and Hopital^ Saint-Joseph, Paris, France 2WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Department of Laboratory Medicine, Microbiology, Orebro€ University Hospital and Orebro€ University, Orebro,€ Sweden 3Syphilis National Reference Center, Hopital^ Tarnier-Cochin, AP-HP, Paris, France 42nd Dermatological Clinic, Carol Davila University, Colentina Clinical Hospital, Bucharest, Romania 5Department of Dermatovenereology, University Medical Centre Ljubljana, Ljubljana, Slovenia 6Department of Genitourinary Medicine, the Royal South Hants Hospital, Southampton, UK *Correspondence to: M. Janier. E-mail: [email protected] Abstract The 2020 edition of the European guideline on the management of syphilis is an update of the 2014 edition. Main modifications and updates include: - The ongoing epidemics of early syphilis in Europe, particularly in men who have sex with men (MSM) - The development of dual treponemal and non-treponemal point-of-care (POC) tests - The progress in non-treponemal test (NTT) automatization - The regular episodic shortage of benzathine penicillin G (BPG) in some European countries - The exclusion of azithromycin as an alternative treatment at any stage of syphilis - The pre-exposure or immediate post-exposure prophylaxis with doxycycline in populations at high risk of acquiring syphilis. Received: 12 June 2020; Accepted: 4 September 2020 Conflicts of interest The authors have no conflicts of interest related to this guideline. Funding sources None. Introduction EEA countries and particularly among men who have sex with Syphilis is a systemic human disease due to Treponema pallidum men (MSM).3 subsp.
    [Show full text]
  • WHO GUIDELINES for the Treatment of Treponema Pallidum (Syphilis)
    WHO GUIDELINES FOR THE Treatment of Treponema pallidum (syphilis) WHO GUIDELINES FOR THE Treatment of Treponema pallidum (syphilis) WHO Library Cataloguing-in-Publication Data WHO guidelines for the treatment of Treponema pallidum (syphilis). Contents: Web annex D: Evidence profiles and evidence-to-decision frameworks - Web annex E: Systematic reviews for syphilis guidelines - Web annex F: Summary of conflicts of interest 1.Syphilis – drug therapy. 2.Treponema pallidum. 3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154980 6 (NLM classification: WC 170) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/ copyright_form/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Leptospirosis: a Waterborne Zoonotic Disease of Global Importance
    August 2006 volume 22 number 08 Leptospirosis: A waterborne zoonotic disease of global importance INTRODUCTION syndrome has two phases: a septicemic and an immune phase (Levett, 2005). Leptospirosis is considered one of the most common zoonotic diseases It is in the immune phase that organ-specific damage and more severe illness globally. In the United States, outbreaks are increasingly being reported is seen. See text box for more information on the two phases. The typical among those participating in recreational water activities (Centers for Disease presenting signs of leptospirosis in humans are fever, headache, chills, con- Control and Prevention [CDC], 1996, 1998, and 2001) and sporadic cases are junctival suffusion, and myalgia (particularly in calf and lumbar areas) often underdiagnosed. With the onset of warm temperatures, increased (Heymann, 2004). Less common signs include a biphasic fever, meningitis, outdoor activities, and travel, Georgia may expect to see more leptospirosis photosensitivity, rash, and hepatic or renal failure. cases. DIAGNOSIS OF LEPTOSPIROSIS Leptospirosis is a zoonosis caused by infection with the bacterium Leptospira Detecting serum antibodies against leptospira interrogans. The disease occurs worldwide, but it is most common in temper- • Microscopic Agglutination Titers (MAT) ate regions in the late summer and early fall and in tropical regions during o Paired serum samples which show a four-fold rise in rainy seasons. It is not surprising that Hawaii has the highest incidence of titer confirm the diagnosis; a single high titer in a per- leptospirosis in the United States (Levett, 2005). The reservoir of pathogenic son clinically suspected to have leptospirosis is highly leptospires is the renal tubules of wild and domestic animals.
    [Show full text]
  • Gonorrhea, Chlamydia, and Syphilis
    2019 GONORRHEA, CHLAMYDIA, AND SYPHILIS AND CHLAMYDIA, GONORRHEA, Dedication TAG would like to thank the National Coalition of STD Directors for funding and input on the report. THE PIPELINE REPORT Pipeline for Gonorrhea, Chlamydia, and Syphilis By Jeremiah Johnson Introduction The current toolbox for addressing gonorrhea, chlamydia, and syphilis is inadequate. At a time where all three epidemics are dramatically expanding in locations all around the globe, including record-breaking rates of new infections in the United States, stakeholders must make do with old tools, inadequate systems for addressing sexual health, and a sparse research pipeline of new treatment, prevention, and diagnostic options. Lack of investment in sexual health research has left the field with inadequate prevention options, and limited access to infrastructure for testing and treatment have allowed sexually transmitted infections (STIs) to flourish. The consequences of this underinvestment are large: according to the World Health Organization (WHO), in 2012 there were an estimated 357 million new infections (roughly 1 million per day) of the four curable STIs: gonorrhea, chlamydia, syphilis, and trichomoniasis.1 In the United States, the three reportable STIs that are the focus of this report—gonorrhea, chlamydia, and syphilis—are growing at record paces. In 2017, a total of 30,644 cases of primary and secondary (P&S) syphilis—the most infectious stages of the disease—were reported in the United States. Since reaching a historic low in 2000 and 2001, the rate of P&S syphilis has increased almost every year, increasing 10.5% during 2016–2017. Also in 2017, 555,608 cases of gonorrhea were reported to the U.S.
    [Show full text]
  • Syphilis NSW Control Guideline for Public Health Units
    Syphilis NSW Control Guideline for Public Health Units Revision history Version Date Revised by Changes Approval 1.0 01/06/2015 CDWG Revision CDNA/AHPPC 1.1 01/08/2016 CDB Case definition CHO 2.0 09/2016 CDB Update to align with the Syphilis Series of CHO National Guidelines (SoNG) v1.0 (endorsed 15 Jan 2015, released 21 Aug 2016), localised for NSW as indicated by [hard brackets]. 3.0 20/03/2019 CDB Update to align with the Syphilis Series of CHO National Guidelines (SoNG) v1.1 (endorsed 17 July 2018, released 03 Aug 2018), localised for NSW as indicated by [hard brackets]. 4.0 04/10/2019 CDB Update to implement timely follow-up of all CHO women of reproductive age in line with changing epidemiological trends in NSW as indicated by [hard brackets] 4.1 13/05/2021 CDB Updated to align with National Syphilis CHO (congenital) case definition v1.3 (endorsed 24 September 2020, implemented 1 January 2021, published 13 January 2021) 1. Summary ........................................................................................................................ 2 2. The disease ..................................................................................................................... 3 3. Routine prevention activities ............................................................................................. 5 4. Surveillance objectives ..................................................................................................... 5 5. Data management ..........................................................................................................
    [Show full text]
  • Laboratory Diagnostic Testing for Treponema Pallidum
    Laboratory Diagnostic Testing for Treponema pallidum Expert Consultation Meeting Summary Report January 13‐15, 2009 Atlanta, GA This report was produced in cooperation with the Centers for Disease Control and Prevention. Laboratory Diagnostic Testing for Treponema pallidum Expert Consultation Meeting Summary Report January 13‐15, 2009 Atlanta, GA In the last decade there have been major changes and improvements in STD testing technologies. While these changes have created great opportunities for more rapid and accurate STD diagnosis, they may also create confusion when laboratories attempt to incorporate new technologies into the existing structure of their laboratory. With this in mind, the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL) convened an expert panel to evaluate available information and produce recommendations for inclusion in the Guidelines for the Laboratory Diagnosis of Treponema pallidum in the United States. An in‐person meeting to formulate these recommendations was held on January 13‐15, 2009 on the CDC Roybal campus. The panel included public health laboratorians, STD researchers, STD clinicians, STD Program Directors and other STD program staff. Representatives from the Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) were also in attendance. The target audience for these recommendations includes laboratory directors, laboratory staff, microbiologists, clinicians, epidemiologists, and disease control personnel. For several months prior to the in‐person consultation, these workgroups developed key questions and researched the current literature to ensure that any recommendations made were relevant and evidence based. Published studies compiled in Tables of Evidence provided a framework for group discussion addressing several key questions.
    [Show full text]
  • CHLAMYDIOSIS (Psittacosis, Ornithosis)
    EAZWV Transmissible Disease Fact Sheet Sheet No. 77 CHLAMYDIOSIS (Psittacosis, ornithosis) ANIMAL TRANS- CLINICAL FATAL TREATMENT PREVENTION GROUP MISSION SIGNS DISEASE ? & CONTROL AFFECTED Birds Aerogenous by Very species Especially the Antibiotics, Depending on Amphibians secretions and dependent: Chlamydophila especially strain. Reptiles excretions, Anorexia psittaci is tetracycline Mammals Dust of Apathy ZOONOSIS. and In houses People feathers and Dispnoe Other strains doxycycline. Maximum of faeces, Diarrhoea relative host For hygiene in Oral, Cachexy specific. substitution keeping and Direct Conjunctivitis electrolytes at feeding. horizontal, Rhinorrhea Yes: persisting Vertical, Nervous especially in diarrhoea. in zoos By parasites symptoms young animals avoid stress, (but not on the Reduced and animals, quarantine, surface) hatching rates which are blood screening, Increased new- damaged in any serology, born mortality kind. However, take swabs many animals (throat, cloaca, are carrier conjunctiva), without clinical IFT, PCR. symptoms. Fact sheet compiled by Last update Werner Tschirch, Veterinary Department, March 2002 Hoyerswerda, Germany Fact sheet reviewed by E. F. Kaleta, Institution for Poultry Diseases, Justus-Liebig-University Gießen, Germany G. M. Dorrestein, Dept. Pathology, Utrecht University, The Netherlands Susceptible animal groups In case of Chlamydophila psittaci: birds of every age; up to now proved in 376 species of birds of 29 birds orders, including 133 species of parrots; probably all of the about 9000 species of birds are susceptible for the infection; for the outbreak of the disease, additional factors are necessary; very often latent infection in captive as well as free-living birds. Other susceptible groups are amphibians, reptiles, many domestic and wild mammals as well as humans. The other Chlamydia sp.
    [Show full text]
  • Psittacosis/ Avian Chlamydiosis
    Psittacosis/ Importance Avian chlamydiosis, which is also called psittacosis in some hosts, is a bacterial Avian disease of birds caused by members of the genus Chlamydia. Chlamydia psittaci has been the primary organism identified in clinical cases, to date, but at least two Chlamydiosis additional species, C. avium and C. gallinacea, have now been recognized. C. psittaci is known to infect more than 400 avian species. Important hosts among domesticated Ornithosis, birds include psittacines, poultry and pigeons, but outbreaks have also been Parrot Fever documented in many other species, such as ratites, peacocks and game birds. Some individual birds carry C. psittaci asymptomatically. Others become mildly to severely ill, either immediately or after they have been stressed. Significant economic losses Last Updated: April 2017 are possible in commercial turkey flocks even when mortality is not high. Outbreaks have been reported occasionally in wild birds, and some of these outbreaks have been linked to zoonotic transmission. C. psittaci can affect mammals, including humans, that have been exposed to birds or contaminated environments. Some infections in people are subclinical; others result in mild to severe illnesses, which can be life-threatening. Clinical cases in pregnant women may be especially severe, and can result in the death of the fetus. Recent studies suggest that infections with C. psittaci may be underdiagnosed in some populations, such as poultry workers. There are also reports suggesting that it may occasionally cause reproductive losses, ocular disease or respiratory illnesses in ruminants, horses and pets. C. avium and C. gallinacea are still poorly understood. C. avium has been found in asymptomatic pigeons, which seem to be its major host, and in sick pigeons and psittacines.
    [Show full text]
  • Chlamydia Trachomatis Neisseria Gonorrhoeae
    st 21 Expert Committee on Selection and Use of Essential Medicines STI ANTIBIOTICS REVIEW (1) Have all important studies/evidence of which you are aware been included in the application? YES (2) For each of the STIs reviewed in the application, and noting the corresponding updated WHO treatment guidelines, please comment in the table below on the application’s proposal for antibiotics to be included on the EML STI ANTIBIOTICS USED IN WHO AND RECOGNIZED GUIDELINES Chlamydia trachomatis UNCOMPLICATED GENITAL CHLAMYDIA AZITHROMYCIN 1g DOXYCYCLINE 100mg TETRACYCLINE 500mg ERYTHROMYCIN 500mg OFLOXACIN 200mg ANORECTAL CHLAMYDIAL INFECTION DOXYCYCLINE 100mg AZITHROMYCIN 1g GENITAL CHLAMYDIAL INFECTION IN PREGNANT WOMEN AZITHROMYCIN 1g AMOXYCILLIN 500mg ERYTHROMYCIN 500mg LYMPHOGRANULOMA VENEREUM (LGV) DOXYCYCLINE 100mg AZITHROMYCIN 1g OPHTHALMIA NEONATORUM AZITHROMYCIN SUSPENSION ERYTHROMYCIN SUSPENSIONS FOR OCULAR PROPHYLAXIS TETRACYCLINE HYDROCHLORIDE 1% EYE OINTMENT ERYTHROMYCIN 0.5% EYE OINTMENT POVIDONE IODINE 2.5% SOLUTION (water-based) SILVER NITRATE 1% SOLUTION CHLORAMPHENICOL 1% EYE OINTMENT. Neisseria gonorrhoeae GENITAL AND ANORECTAL GONOCOCCAL INFECTIONS CEFTRIAXONE 250 MG IM + AZITHROMYCIN 1g CEFIXIME 400 MG + AZITHROMYCIN 1g SPECTINOMYCIN 2 G IM ou CEFTRIAXONE 250 MG IM ou CEFIXIME 400 MG OROPHARYNGEAL GONOCOCCAL INFECTIONS CEFTRIAXONE 250 MG IM + AZITHROMYCIN 1g CEFIXIME 400 MG + AZITHROMYCIN 1g CEFTRIAXONE 250 MG IM RETREATMENT IN CASE OF FAILURE CEFTRIAXONE 500 mg IM + AZITHROMYCIN 2g CEFIXIME 800 mg + AZITHROMYCIN 2g SPECTINOMYCIN 2 G IM + AZITHROMYCIN 2g GENTAMICIN 240 MG IM + AZITHROMYCIN 2g OPHTALMIA NEONATORUM CEFTRIAXONE 50 MG/KG IM (MAXIMUM 150 MG) KANAMYCIN 25 MG/KG IM (MAXIMUM 75 MG) SPECTINOMYCIN 25 MG/KG IM (MAXIMUM 75 MG) FOR OCULAR PROPHYLAXIS, TETRACYCLINE HYDROCHLORIDE 1% EYE OINTMENT ERYTHROMYCIN 0.5% EYE OINTMENT POVIDONE IODINE 2.5% SOLUTION (water-based) SILVER NITRATE 1% SOLUTION CHLORAMPHENICOL 1% EYE OINTMENT.
    [Show full text]
  • My Story About My Journey
    My Story • Name: Ingeborg Kuiper • Age: • My address is: • My postal address is: [same as above] • You can contact me on: • I want my story to be public. About my journey I acquired Lyme-like illness at home, in QLD. It started when I hugged my dog. Hours later, I was scratching at an itch in my neck. When I looked closer, I noticed it was a small tick. I started to get sick several days later. I was born in the Netherlands (ie outside of Australia) and had also travelled to Europe about 8 months before getting sick. While this means my case of Lyme disease is difficult to prove as being acquired in Australia, it is extremely unlikely that I acquired Lyme while in Europe. This is because I had been living in Australia for 15 years with no health problems and the recent trip to Europe was in the middle of winter, when ticks are inactive. Also, I am not aware of having been bitten by any ticks while in Europe, while I know I was bitten by a tick in Australia a few weeks before getting sick. Type of Bite: tick bite. I was relatively lucky, because I was able to get an accurate diagnosis within months of getting sick. This was as a result of sending blood samples overseas. I have since met many people with Lyme who took years to find out why they were sick; and these people tend to take a very long time to recover, even with effective treatment from overseas.
    [Show full text]